

References

- Abdel-Wahed MA; Awad HA; El-Barbary MN; Abbaas W (2001):** Focal infections in neonates recovering from generalized sepsis: The value of serial CRP measurement. *The Egyptian Journal of Neonatology*; (2): 2.
- Aliff TB; Maslak PG; Jurcic JG (2003):** Refractory Aspergillus pneumonia in patients with acute leukaemia: successful therapy with combination capsosfungin and liposomal amphotericin B. *Cancer*; 97: 1025-1032.
- Aly R; Frney R; Ayles CB (2001):** Treatments for common superficial fungal infections. *Dermatol Nurs*; 13 (2): 91-94, 98-99.
- Arthington-Skaggs BS; Jardi H; Desai T; Morrison CJ (2000):** Quantization of ergosterol content: Novel method for determination of fluconazole susceptibility of *C. albicans*. *J Clin Microbiol*; 37 (9): 3332-3337.
- Ascioglu S; Rex JH; de Pauw B; Bennet JE; Bille J (2002):** Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplantations: an international consensus. *Clin Infect Dis*; 34 (1): 7-14.
- Baley JE; Kliegman RM; Boxerbaum B; Fanaroff AA (1986):** Fungal colonization in the very low birth weight infant. *Pediatrics*; 78: 225-32.
- Bar W and Hecker H (2002):** Diagnosis of systemic *Candida* infections in patients of intensive care unit. Significance of serum antigens and antibodies. *Mycosis*; 45 (1-2): 22-28.

- Beak SH; Chae D; Hough D; Byum B; Cho (1998):** Detection and differentiation of causative fungi of onychomycosis using PCR amplification and restriction enzyme analysis. *Int. J. Dermatol*; 37: 682-686.
- Benjamin DK Jr; Ross K; McKinney RE Jr; Auten R; Fisher RG (2000):** When to suspect fungal infection in neonates: a clinical comparison of *Candida albicans* and *Candida parapsilosis* fungemia with coagulase-negative staphylococcal bacteremia. *Pediatrics*; 106: 712-718.
- Benjamin DK; Belong ER; Steinbach WJ; Cotton CM; Walsh TJ; Clark RH (2003):** Empirical therapy for neonatal candidemia in VLBW infants. *Pediatrics*; 112: 543-547.
- Bennett JE (1998):** Fungal infections. In: *Hamson's principles of internal medicine*, 14th edn. Vol. 1 Ch. 202, P: 1148-1163. Fauci A.S.; Braunwald E.; Jsselbacher KA. et al. Eds. McGraw-Hill, New York.
- Bodey GP (1993):** Antifungal agents. In: Bodey G.P. (edr): *Candidiasis*. P: 371. New York, Raven Press.
- Bojkova K and Vassileva P (2001):** Microbiology study of vulvovaginitis in children. 11th European Congress of Clinical Microbiology and Infectious Diseases, Istanbul, Turkey. P: 121 (Congress abstract_book).
- Botas CM; Kurlat I; Younf SM; Sola A (1995):** Disseminated candidal infections and intravenous hydrocortisone in preterm infants. *Pediatr*; 95: 883-7.
- Bow YF; Herwaldt LA; Pfaller MA (1999):** Trends in antifungal use and epidemiology of nosocomial yeast infections in a university Hospital. *J Clin Microbiol*; 37: 531-537.

- Brasch J (2004):** standard and recently developed methods for the differentiation of derma-rophytes. *Hautarzt*. Feb.; 55(2):136-142.
- Brenner GM (2000):** Antifungal drugs. In: *Pharmacology*, 1st edn. Ch. 42, P; 441-447. W.B. Saunders Company, Philadelphia.
- Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R (2005):** Caspofmgin as first line therapy of pulmonary invasive fungal infections in 32 immunocompro-mised patients with hematologic malign-nancies *Eur J Haematol*; 75 (3)-.227-233.
- Carpenter CHF and JR Maenza (2001) :** Candidiasis. In: *Current therapy of infect. Dis.*, 2nd edn. P: 696-699. Scholss-berg D. edr. Mosby International Limited, London.
- Chaaib F; Qaeiroz EF; Ndjoko K; Diallo D; Hostettmann K; (2003):** Antifungal and antioxidant compounds from the root bark of fagara zanthoxyloides. *Planta Med.* Apr.; 69 (4): 316-320.
- Chan F; Buchheidt D; Skladny H; Baust C; Hehlmann R (2002):** Systemic infections with *Candida* spp. and *aspergillus* spp. in immunocompremised patients with hematological malignancies; 46 (3): 219-228 [abstract].
- Crislip MA and JE Edwards (1992):** *Candida albicans* and related species. In: *Infectious diseases* 1st edn., Ch. 283, P: 1887-1894. Gorbach S.L., Bartllett J.G. and Blacklow N.R. edr., Saunders W.B. Company, Philadelphia, Pennsylvania.
- Darkes, MJ; Scott LJ; Goo KL; (2003):** Terbinafme: a review of its use in onychomycosis in adults *Am J Clin Dermatol*; 4 (1): 39-65.

- De Vroey C; Desmet P; LI ZQ; Mukamurangwa P; Raes-Wuytack C (1996):** Farther studies on the in vitro antifungal activity of amorolfine. *Mycosis.*; 39: 41-44.
- Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecf D; Theiel E; Hass A; Ruhnke M; Lode H (2003):** Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. *Clin Infect Dis*; 34: 564-56-71.
- Diaz MR and Fell JW (2004):** High-Throughput Detection 5th of Pathogenic Yeast of the Genus *Trichosporon* *J Clin Microbiol*; 42: 3696-3706.
- Dick SD and Rosengard BR (1985):** Fatal disseminated candidiasis to an amphotericin B resistant *C. guilliermondii*, *Ann Intern Med*; 102: 67-68.
- Dixon DM; Rhodes SC; Fromnung RA (1999).** Taxonomy, classification and morphology of the fungi. In: *Manual of Clin. Microbiol.*, 7th edn. Ch. 93, P: 1161-1166. Murray P.R., Baron E.J. and Pfaller M.A. eds. ASM, Washington DC.
- Dutta S; Murki S; Varma S; Narang A; Chakrabarti A (2005):** Effects of cessation of a policy of neonatal fluconazole prophylaxis on fungal resurgence. *Indian Pediatr*; 42: 1226-30.
- Edman JC (1995):** Medical mycology. In: *Medical microbiology*. 20th edn. Ch. 45, P:555-556. Brook G.F., Butel J.S., and Omston LN eds. Copy right by Appleton & Lange.
- Edwards JE (1995):** *Candida* species. In: *Principles and practice of Infect. Dis*. 4th edn. P: 2289-2305. Mandell GL, Bennett JE, Dolin R eds. Churchill Livingstone, New York.

Ellis MD Spence, De Pauw B (1998): An EORTC international multicenter randomized trial (EORTC number19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis Clin infect Dis;27:1406-1412

El-Mohandes AE; Johnson-Robbins L; Keiser JF; Simens SH; Aure MV (1994): Incidence of Candida parasitosis colonization in an intensive care nursery population and its association with invasive fungal disease. Pediatric Infectious Disease Journal; 31: 520-4.

Espinel A and Pfaller M (1992): Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests J Clin Microbiol.; 30 (10): 3138-3145.

Espinel A; White TH; Pfaller MA (1999): Antifungal agents and susceptibility tests. In: Manual of clin. Microbiol., 7th edn. Ch. 126, P: 1640-1652. Murray PR; Baron EJ, Pfaller MA edn. ASM, Washington DC.

Favre B and Ryder NS (1996): Characterization of squalene epoxidase activity from the dermatophyte *Trichophyton rubrum* and its inhibition by Terbinafine and other antimycotic agents. Antimicrob. Ag. Chemother. 40: 443-447.

Fisher JF and Cook NB (1998): Yeasts and yeast like organisms. In: Fundamentals of Diagnostic Mycology 1st edn., Ch. 7, P: 196-230. WB Saunders Company, Philadelphia, London, Toronto.

- Flahaut MD; Sanglard M; Monod S; Bille M; Rossier (1998):** Rapid detection of *C. albicans* in clinical samples by DNA amplification of common regions from *C. albicans* secreted aspartic proteinase genes. *J Clin Microbiol*; 36 (2): 395-401.
- Forbes BA; Sahn DF; Weissfeld AS (2002):** Mycology p. 711-798. In. Bailey & Scott's Diagnostic Microbiology, 11th edition. Mosby, Inc. St. Louis, Missouri.
- Garcia-Rwz JC; Arilla MC; Regulez P; Quindos G; Alvarez A; Ponton J (1997):** detection of antibodies to *Candida albicans* germ tubes for the diagnosis and therapeutic monitoring of invasive candidiasis in patients with haematological malignancies. *J Clin Microbiol*; 35: 3284-3287.
- Garro M; Henart H; Laffler J; Reitze H; Engel A; Shumacher V; Klugebiel T (2000):** Prospective screening by panfungal J polymerase chain reaction assay in I patients at risk for fungal infection. *Br J Haematol*; 111: 635-640.
- Geha A and Roberts F (1994):** Diagnosis of fungal ; infection: New technologies for the ! mycology laboratory. *Transpl Infect Dis*; 4 ! (3): 32-7.
- Gilepie SH and Bamford KB (2000):** Yeast infections. In: Medical microbiology and infection at a glance, 1st edn. Ch. 32. P: 70-71. Black Well Science Limited, London.
- Glasmacher A; PrenticeA; Gorschluter M (2003):** Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3,597 patients. *J Clin Oncol*; 21: 4615-4626.

- Groll AH and Walsh TJ (2001):** Capsfungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. *Expert Opin Investig Drugs*; 10: 1545-1558.
- Guaro and Gene S (1995):** Risk factors for fungal infection in neonates. *Clin Int Dis*; 18: 525-532.
- Gustafson KS; Vercellotti GM; Bendel CM; Hostetter MK (1991):**
Molecular mimicry in *C. albicans*, role of an integrin analogue in adhesion of the yeast to human endothelium.
J Clin Invest; 87: 1986-1992.
- Hay RL (1996):** Yeast infection. *Cutaneous Mycology. Dermatologic Clinics.*; 14: 113-124.
- Hazen KG and Howell SA (2003):** Candida, Cryptococcus, and other yeasts of medical importance. In: *Manual of clinical microbiology 8th edn.* Ch. 114, P; 1693-1711. Murray PR; Baron E, and Pfaller MA, eds. ASM, Washington DC.
- Hazen KG; Theisz GW; Howell SA (1999):** Chronic UTI due to *Candida utilis*, *J Clin Microbiol*; 37 (3): 824-827.
- Herbrecht R; Denning DW; Patterson RF (2002):** Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med*; 347: 408-415.
- Hovi S; Girmenia C; Nuzzi M; Martino P (2000):** Clinical significance of aspergillus fungemia in patients with hematologic malignancies. *Br J Haematol*; 111: 634-635.

- Hoy SF (1998):** Antinmgal drugs. In: The use of antibiotics. A clinical Review of Antibacterial, Antifungal and Antiviral Drugs 5th edn. Ch. 4, P: 1245-1505. Kucers A, Crowe SM, Grayson ML and Hoy JF edr., Buffer Worth Heinemann.
- Huttova M; Filka J; Kurak J; Kralinsky K; Krcmery V Jr (1998):** Candida fungemia in neonates treated with fluconazole. *Pediatr Infect Dis J*; 17: 12-15.
- Iruretagoyena JR; Regulez P; Quindos Q; Ponton J; (2009):** antibodies to Candida albicans germ tube in two intensive care patients with invasive candidiasis. *Rev Iberoam Micol*; 17: 93-96.
- Jabra-Rizk MA; Falkler JRW; Merz WG (2000):** Retrospective identification and characterization of Candida dubliniensis isolates among C.albicans clinical laboratory isolated from human immunodeficiency virus (HTV) infected and non-HIV infected individuals. *J Clin Microbiol*; 38 (6): 2423-2426.
- Jaeger EEM; Carroll NM; Choudhury S; (2000):** Rapid detection and identification of Candida, Aspergilltis, and Fusarium species in ocular samples using nested PCR *J Clin Microbiol*; 38 (8): 2902-2908.
- Jarvis WR (1996):** The epidemiology of colonization. *Infect Control Hosp Epidemiol*; 17: 47-52.
- Jeffrey B; Campbell F; Glen Seidel; Edmond T; Gonzales JR (2004):** Use of a mechanical thrombectomy catheter for percutaneous extraction of renal fungal bezoars in a premature infants; *589e6: 589e8*.

- Jirkpatrick WR; Turner TM; Fothergill AW; McCaathy DI; Redding SW; Patterson RF (2000):** Fluconazole disk diffusion susceptibility testing of *Candida* species. *J Clin Microbiol*; 36 (11): 3429-3432.
- Jobe DA; Callister SM; Lovrich SD; Schell RF (1999):** Rapid susceptibility testing of lyme disease spirochetes by flow cytometry. *J Spiro Tick disease*; 6 (3): 105-111.
- Johnson MD; MacDougall C; Ostrosky-Zeichner L (2004):** Combination antifungal therapy. *Antimicrob Agents Chemother*; 48: 693-715.
- Kami MU; Macida K; Okuzmi T; Matusumura T; Mori S (2002):** Effect of fluconazole prophylaxis on fungal blood cultures. *Br J Haematol*; 117 (1): 40-46.
- Kantarcioglu AS (2001):** Detection of phospholipase and protease production in clinical isolates of *Candida* species. 11th European Congress of Clinical Microbiology and infectious disease; Istanbul, Turkey; P: 340 (Congress abstract book).
- Kaufman L and Reiss E (1992):** Sero diagnosis of fungal diseases. In: *Manual of Clinical Laboratory Immunology*, 4th edn, P: 506-528. Rose NR and Macario EC eds. ASM Press, Washington DC.
- Khan Z; Abmad S; Mustafa AS; Chugh TD (2001):** Rapid detection and identification of medically important *Candida* species by nested PCR. 11th European Congress of Clin. Microbiol and Infect Dis. Istanbul, Turkey, P: 121, (Congress abstract book).

Koneman EW; Alien SD; Janda WM; Schreckenberger PC; Winn WC (1997): Antimicrobial susceptibility testing. In: Color Atlas and Textbook of Diagnostic Microbiology, 5th edn., Ch 15, P: 787-856. Lippincott Company, Philadelphia, New York .

Kontoyannis DP; Hachem R; Lewis RE (2003): Efficacy and toxicity of capsosfungin in combination with with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. *Cancer*; 98: 292-299.

Krcmery S (2001): Usual and unusual risk factors of infection in cancer patients. 11th European Congress of Clin. Microbiol and Infect. Dis. Istanbul; Turkey, P: 37 (Congress abstract book).

Krcmery S; Dubrava M; Krcmery VJ (1999): Fungal urinary tract infections in patients risk. *Int J Antinaicrob Agents*. 11 (3): 389-391.

Kusene S and Shapiro M (1998): Invasive yeast infections other than *Candida* spp. In: *Acute leukemia. Hosp Infect*; 41 (3): 181-194.

Kwon-Chung KJ and Bennett JE (1992): Candidiasis. In: *Medical mycol*; P: 280-337. Lea an Febiger Philadelphia.

Labraca JA; Grasmick EA; Kokkinos HM; Brickner DA (1998): Critical evaluation of 4 weeks incubation for fungal cultures: is the fourth weeks useful? *J Clin Microbiol*; 35: 53-58.

- Larocco MT (2002):** Reagents, Stains, and Media: Mycology, P 1686-1692. In: Murray PR (ed.) Manual of Clinical Microbiology, 8th edition. ASM Press, Washington, DC.
- Lee S; Lu J; Chen C; Chi W (2001):** Antifungal susceptibility testing of *Candida* isolates from blood stream infections. 11th European Congress of Clin. Microbiol and Infect Dis. Istanbul, Turkey, P: 171 (Congress abstract book).
- Leibovitz E; Luster-Reicher A; Amitai M; Mogilner B (2006):** Neonatal candidiasis: Clinical picture, management controversies and consensus, and new therapeutic options; 49: SI, 69-73.
- Lenderman MM (2001):** Infections of the urinary tract. In: Andreoli Cecil essential of medicine, 5th edn. Ch. 105, P: 825-827. Carpenter CCJ, Griggas RC and Loscalzo J, edr. WB Saunders Company, Philadelphia.
- Lequaglie CG; Basilico M; Massone PB (1998):** Lyposomal antifungal therapy and low toxicity in thoracic cancer patients in ICU. 8th International Congress of Infect. Dis Boston Massachusetts, USA, P: 96 (Congress abstract book).
- Levy J; Shalit I; Eirk E; Sirota L; Ashkenazo S; German B; Linder N (2006):** *Candida* endocarditis in neonates: report of five cases and review of the literature: Mycoses; 49: 43-48.
- Linda RK; Elie CM; Clayton CE; Ciblak MA (2000):** Comparison of a new colorimetric assay with NCCLS broth microdilution method (M27-A) for antifungal drug MIC determination. J Clin Microbiol; 38 (6): 2334-2338.

Liu KH; Wu CJ; Chou HC; Lee NT Hung ST; Ko WC (2002):

Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. *J Clin Microbiol*; 42 (12): 5950-5953.

Lopez SN; Sortino M; Escalate A; De Campos F; Correa R;

Zacchino SA (2003): Antifungal properties of novel N-alpha, beta and beta-substituted succinimides against dermatophytes. *Arzneimittel-forschung*; 53 (4): 280-288 [abstract].

Luna MA and Tortoedo ME (1993): Histologic identification and

pathologic patterns of disease caused by *Candida*. In: *Candidiasis: Pathogenesis, Diagnosis, and Treatment*, 2nd edn. P: 21-42. edr. Bodey GP, Raven Press, New York.

Lyon R and Woods G (1995): Comparison of the BacT/Alert and

ISOLATOR blood culture systems for recovery of fungi. *Am J Clin Pathol*; 103: 660-662 .

Maertens J and Boogaerts M (2005): The place for itraconazole in

treatment. *J Antimicrob Chemother*; 56 Suppl; 1:133-138.

Makhoul IR; Sujov P; Smolkin T; Lusky A; Reichman B (2002):

Epidemiological, clinical and microbiological characteristics of late-onset sepsis among very low birth weight infants: a national survey. *Pediatrics*; 109: 34-39.

Makhoul RI; Kassis I; Smolkin T; Tamir A; Sujov P (2001): Review

of 49 neonates with acquired fungal sepsis: Further characterization. *Pediatrics*; (1): 107.

- Manzoni P; Arisio R; Mostent M; Leonessa M; Farina D; Agnes M; et al. (2006):** Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates; 22: 32.
- Marinez JP; Gil ML; Rihot JL; Chafflo WL (1998):** Serologic response to cell wall mannoproteins and protein of *C. albicans*. *CLIn Microbiol Rev*; 11 (1): 121-141.
- Marr K; Crippa F; Leisenring W (2004):** Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplant. *Blood*; 103: 1527-1533.
- Mayer F; Magadia R; Weinstein P (2004):** Laboratory diagnosis of bacteremia and fungemia. *Clin Infect Dis*; 15 (4): 1009-24.
- McCullough BP; Keating C; Cuman MD; McMullin MF (1999):** Identification of medically important pathogenic fungi reference strand-mediated conformational analysis. *J Med Microbiol*; 51 (6): 468-478.
- McDonald LC; Weinstein MP; Fune J; Mirrett S; Reimer LG; Reller LB (2000):** Controlled comparison of BacT/ALERT FAN aerobic medium and BACTEC fungal blood culture medium for detection of fungemia. *J Clin Microbiol*; 39: 622-624.
- Merz WC and Roberts GD (1999):** Algorithms for detection and identification of fungi. In: *Manual of clinical microbiology*. 7th edn. Ch 94; P. 1167-1183. Murray PR, Baron E, Tenover FC, Tenover FC, eds. ASM, Washington DC.

- Morace G; Pagano L; Saguinetti M; Posteraro B; Mele L; et al. (1999):** PCR-Restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. *J Clin Microbiol*; 37 (6): 1871-1875.
- Morace GM; Sanguinetti B; Posteraro GL; Fadda G (1997):** Identification of various medically important Candida species in clinical specimens by PCR-Restriction enzyme analysis. *J CLin Microbiol*; 35: 667-672.
- Morello FA; Mansilla AV; and Wallace MJ (2002):** Removal of renal fungus balls using a mechanical thrombectomy device. *AJR AM J Roentgenol*. 178: 1191-1193.
- Mori F and Matsumura S (1999):** Rapid identification of Candida species. *J Clin Microbiol*; 36 (11): 3260-3265.
- Murphy JW (2000):** Cell-mediated immunity and medically related fungi. In: *Effects of microbes on the immune system*, 1st edn. Ch 36, P: 593-621. Cunningham, MW and Fujinami RS, edr. Lipincott Williams and Wilkins, Philadelphia.
- Narang A; Agraeal P; Chakraborti A; Kumar P (1998):** Fluconazole in the management of neonatal systemic candidiasis. *Ind Pediatr*; 33: 823-826.
- Nguyen MH; Peacock JE Jr; Morris AJ; Tanner DC (1996):** The changing face of candidemia: emergence of non-candida albicans species and antifungal resistances. *Am J Med*; 100 (6): 617-23.
- Nucci M and Marr KA (2005):** Emerging fungal diseases. *Clin Infect Dis*; 41 (4): 521-526.
- Odds FC(1988):**Candida and candidiasis,2nd edn,London,Bailliere, Tindal.

- Ostrosky-Zeichner L; Alexander BD; Kett DH; Vazquez J; Pappas PG; Saeki F; Ketchum PA; Wingard J; Schiff R; Tamura H; Finkelamn MA; Rex JH (2005):** Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis*; 41 (5): 654-659.
- Pagano L; Caira M; Fianchi L (2005):** Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. *Ann Med*; 37 (4): 259-269.
- Pappas PH; Rex JH; Sobel JD (2004):** Guidelines for treatment of candidiasis. *Clin Infect Dis*; 38: 161-189.
- Patrick JL; Miller GR; Carr DL (1995):** Rapid calorimetric identification of *C. albicans*. *J Clin Microbiol*; 28 (2): 614-615.
- Peltroche H; Schuitler N; Luticken R; Haase G (1999):** Rapid identification of *C. glabrata* by using a dipstick to detect trehalase-generation glucose. *J Clin Microbiol*; 37 (1):202-205
- Perfect C and Schell M (1996):** Fluconazole resistant pathogen in patients infected with human immunodeficiency virus. *Clin Infect Dis*; 25: 161.
- Persing DH (1991):** Polymerase chain reaction: Trenches to benches. *J Clin Microbiol*; 29 (5): 1281-1285.
- Peterson SW (2000):** Phylogenetic relationships in *Aspergillus* based on rDNA sequence analysis. P. 323-355. In: Samson RA and Pitt JI (ed.), *Integration of modern taxonomic methods for penicillium and aspergillus classification*. Harwood Scientific Publishers; Amsterdam, Netherland.

- Pfaller MA and Diekema DJ (2004):*** Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of *Candida*. *Clin Microbiol Infect*; 10 (Suppl 1): 11-23.
- Pfaller MA; Messer SA; Kanissov A; Bolmstrom A (1998):*** Evaluation of the E test for determining fluconazole susceptibilities of 402 clinical isolates by using three different agar media. *J Clin Microbiol*; 36 (9): 2586-2589.
- Pozdorovkina W; Flemina AM; Beloborodova V (1998):*** Analysis of arabinitol, mannose and mannitolmetabolites of several clinically important fungi in patients with candidiasis and aspergillosis. 8th International Congress of Infect. Dis Boston Massachusetts, USA; P: 95 (Congress abstract book).
- Procop GW; Cockerill FR; Vetter EA; Harmsen WS; Hughes JG; Roberts GD (2000):*** Performance of five agar media for recovery of fungi from isolator blood culture. *J Clin Microbiol*; 38: 3827-3829.
- Rabkin A; Tjanoudaki M; Petriodiu E (2000):*** Fungemia and resistance to antifungal agents in a children's hospital. 11th European Congress of Clinical Microbiology and Infection Diseases. Istanbul, Turkey, P: 170 (Congress Abstract Book).
- Rang HP; Dale MM; Ritter JM (2000):*** Antifungal drugs. In: *Pharmacology*, 4th ed. Ch 45, P: 720-724. Churchill Livingstone, London.

- Rex JH; Pappas PG; Karchmer AW (2003):** A randomized and blinded multicenter trials of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropnic subjects. *Clin Infect Dis*; 36: 1221-1228.
- Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE (2000):** Practice guidelines for the treatment of candidiasis. *Infections Diseases Society of America. CLin Infect Dis*; 30: 662-678.
- Rickerts V; Just-Nubling G; Konrad F; Kern J; Lambrecht EA; Bohme V; Jabobi E; Biales (2006):** Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. *Eur J Clin Microbiol Infect Dis*; 17: 1-6.
- Rinaldi MG (1983):** Invasive aspergilosis. *Rev Infect _Dis*; 5: 1061-1077.
- Ritter JM; Lweis LD; Mant TGK (1999):** Fungal and viral infections. In: *Textbook of clinical pharmacology*, 4th edn. Ch 44; P: 504-519. Arnold, London.
- Rodrigues AG; Oina-Vaz C; MarJh PA; Martinez-Deoliveira J; Fonseca AF (1999):** Regulatory effect of fibronectin on the morphogenesis of *C. albicans*, 9th European Congress of Clin. Microbiol and Infect. Dis Berlin, Germany, P: 391; (Congress abstract book).

- Rodrigues AG; Ouna-Vaz C; Rarnos J (2001):** Impairment of phagocytosis following mycelium formation by *Candida* species, 11th European Congress of Clin. Microbiol and Infect. Dis Istanbul, Turkey, P: 336; (Congress abstract book).
- Rowen JL; Rench MA; Kozinetz CA; Adams JM Jr; Baker CJ (1994):** Endotracheal colonization with *Candida* enhances risk of systemic candidiasis in very low birth weight neonates. *Journal of Pediatrics*; 124: 789-94.
- Rowen JL; Tate JM; Nordoff N; Passarell L; McGinnis MR (1999):** *Candida* isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility. *J Clin Microbiol*; 37: 3735-7.
- Ryan KJ (1994):** *Candida*, *Aspergillus*, and other opportunistic fungi. In: Sherris Medical Microbiology: An introduction to infectious diseases, 3rd edn. Kennethc J Ryan KJ edr. Copyright by Appleton and Lange.
- Ryder NS (1999):** Activity of terbinafine against serious fungal pathogens. *Mycosis*; 42: 115-119.
- Saiman L; Ludington E; Dawson JD; et al. (2001):** Risk factors for *Candida* species colonization of neonatal intensive care unit patients. *Pediatr Infect Dis J*; 20: 1119-1124.
- Saiman L; Ludington E; Pfaller M; et al. (2000):** Risk factors for candidemia in NICU patients. The national epidemiology of mycosis survey study group. *Pediatr Infect Dis J*; 9 (4): 319-24.
- Salkin F and Kurd A (1982):** Opportunistic mycoses. In: Zinsser Microbiology, 20th edn, h 85; P: 1135-1157.

- Samonis G; Daissiou M; Anastassiadou H; et al. (1994):*** Antibiotics affecting gastrointestinal colonization of mice by yeasts. *J Chemotherapy*; 6: 50-2.
- Sanglard D and Bille J (2002):*** Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for the treatment of *Candida* infections. In: *Candida and candidiasis*, ed. Richard A; ASM Press; Washington, DC.
- Sanglard D and Odds FC (2002):*** Resistance of *Candida* species to antifungal agents: molecular mechanisms and clinical consequences. *Lancet Infect Dis*; 2 (2): 73-85.
- Segal E and Elad D (1998):*** *Candida* species and blastoschizomyces capitatus. In: *Topley and Wilson's Microbiology and Microbial Infections*. 9th edn., Vol. 4, Ch 23, P: 423-451. Collier L, Balows A and Sussman M, edr. Arnold, London, Sydney.
- Selerange M; Posteraro B; Paano L; Pagliari G; Mele L; La Sorda M; Franco A; Fadda G (2003):*** Comparison of real-time PCR, conventional PCR and galactomannan antigen detection by enzyme-linked immunosorbant assay using broncho-alveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. *J Clin Microbiol*; 41: 3922-3925.
- Sendid B; Tabouret M; PoiOrot JL; Bonnin A; Caillot D; Poulian D (2003):*** Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic *Candida* species. *J Med Microbiol*; 51 (5): 433-442.

- Sendid B; Tabouret M; Poirot JL; Mathiwu D; Fuit JI Poulian D (1999):** New enzyme immunoassays for sensitive detection of circulating *C. albicans* mannan and antimannan antibodies: Useful combined test for diagnosis of systemic candidiasis. *J Clin Microbiol*; 37 (5): 1510-1517.
- Shellow WVR (2000):** Management of superficial fungal infections. In: Primary care medicine: office evaluation and 1049. Goroll AH and Murlley AG, edr. Lippincott Williams and Wilkins, Philadelphia.
- Shimokawa O and Nakaymal H (2000):** Estimation of minimum sterol 14 ct-Demethylation-mhibitory concentration of azoles in *Candida* yeasts using acetate-mediated growth inhibition: potential utility in susceptibility testing. *J Clin Microbiol*; 38 (8): 2893-2896.
- Sigmundsdottir G; Christensson B; Bjorklund LJ (2000):** Long-term effectiveness of treatment with Terbinafine versus itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. *Arch Dermatol Mar*; 138 (3): 353-357.
- Sobel JD (2001):** Candiduria. In: Current therapy infectious diseases, 2nd edn. P: 234-235. Scgolssberg, edr. Mosby International Limited, London.
- Soicer WJ (2000):** Specific pathogens: Fungi, *Aspergillus* and *Candida*. In: Clinical bacteriology, mycology and parasitology, 1st edn. P: 62-70. Churchill Livingstone, London.
- Sovova M and Sova P (2003):** Pharmaceutical significance of *Allium sativum* L4 antifungal aeeact. *Ceska Slov Farm Mar*; 52 (2): 82-87.

- Stevens M (2000):** Diagnosis of fungal infection in leukemia. *Curr Oncol Rep*; 3 (3): 201-208.
- Summerbell RC (2003):** Aspergillus, Fusarium, Sporothrix, Pityriasis and their relatives, P. 273-498. In: Howard DH (ed.), *Fungi Pathogenic for Humans and Animals*, 2nd ed. Marcel Dekker, Inc, New York, NY.
- Takesue YC; Chiu YC; Wang JH; Lin HC; Su BH; Chiu HH (2004):** Nosocomial blood stream infection in a neonatal intensive care unit of a medical center: A three-year review. *J Microbiol Immunol Infect*; 35 (3): 168-72.
- Trick WE; Fridkin SK; Edwards JR; Hajjeh RA; Gaynes RP (2002):** Secular trend of hospital acquired candidemia among intensive care unit patients in United States during 1989-1999; *Clin Infect Dis* 35: 627-630.
- Verghese SL; Padmaja P; Sutha P; Mathew T; John ES (2000):** Rapid identification of fluconazole resistance using CHROMagar Candida. *Ind. J Pathol. Microbiol*; 43: 343-346.
- Vicente MF; Bassilio A; Cabello A; Pelaez F (2003):** Microbial natural products as a source of antifungals *Clin Microbiol Infect*; 9 (1): 15-32.
- Vigano EF; VasconLE; Agrappi C; and P. Clerici. (2002):** Use of simulated blood cultures for time to detection comparison between BacT/ALERT and BACTEC 9240 blood culture systems. *Diagn. Microbiol Infect. Dis.*; 44: 235-240.
- Wahyingsih R; Freisleben HJ; Sonntag HG; Schuitzer P (2000):** Simple and rapid detection of *C. albicans* DNA in serum by PCR for diagnosis of invasive candidiasis. *J Clin Microbiol*; 38 (8): 3016-3021.

- Walsh TJ and Pizzo A (1998):** Treatment of systemic fungal infections: recent progress and current problems, *Eur J Clin Microbiol*: 7 (3): 460-475.
- Walsh TJ; Ganzalez CE; Piscitelli S (2000):** Correlation between in vitro and in vivo antifungal activities in experimental fluconazole resistant oropharyngeal and esophageal candidiasis *J Clin Microbiol* 38 (6): 2369-2373.
- Walsh TJ; Sable C; DePauw B (2003):** A randomized, double-blind, multicenter trial of capsosungin vs liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients [Abstract M1 761]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology.
- Warren NG and Hazen KC (1999):** Candida, Cryptococcus and other yeasts of medical importance. In: *Manual of clinical microbiology* 7th edn. Ch. 95. P: 1884-1199. Murray PR, Baron EJ and Pfaller MA eds. ASM, Washington B.C.
- Watson WJ; Abzyg MK; DeMuri G; et al. (1999):** Multicenter surveillance of invasive fungal disease in very low birth weight infants. *Pediatr Res*; 45: 275A.
- White TC; Marr KA; Eowden RA (1998):** Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. *Clin Microbiol Rev*; 11: 382-402.
- Wiesner AM; Bendel CM; Jfess DJ; Eriandsen SL (2002):** Adherence of yeast and filamentous forms of *C. albicans* to cultured enterocytes *Grit Care Med*; 30 (3): 677-683.

- Wilson J (2000):** A guide to fungi, protozoa, helminthes and ectoparasites. In: Clinical microbiology: an introduction for health care professionals, 8th edn. Ch 10, P: 219-239. Bailliere Tindall, London.
- Wingard JR (2004):** Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis; 39 (1): S38-S43.
- Wingard JR (1995):** Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis; 20 (1): 115-125.
- Winn W; Alien S; Janda W; Koneman E; Procop G; Schreckenberger P; Woods G (2006):** Mycology In: Komeman's color atlas and textbook of diagnostic microbiology. 6th ed.; Lippincott Williams and Wilkins.
- Winston DJ; Maziarz RT; Chandrasekar PH (2003):** Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med.; 138 (9): 705-713.
- Winter JSD (1992):** Fetal and neonatal adrenocortical physiology. In: Polin RA; Fox WW; eds. Fetal and Neonatal Physiology, Philadelphia: WB Saunders; 2: 1829-1841.
- Wu T and Samaranayake LP (1999):** The expression of secreted aspartyl proteinases of Candida species in human whole saliva. J Med Microbiol; 48 (8): 711-720.

Yoshida M; Obayashi A; Iwama A; Ito M; Tsunoda S; Suzuki T; Muroi K; Ohta M; Sakamoto S; Miurcl Y (1997): Detection of plasma (1->3)-p-D-glucan in patients with Fusarium, Trichosporon, Saccharo-myces and Acremomum ftmgaemias J Med Vet Mycol; 35: 371-374.

Yuen C; Dick SD; Rosegard BR (1997): Fetal disseminated candidiasis. Ann Intern Med; 102: 67-68.

Zaas AK and Alexander BD (2005): Echinocandins: role in antifungal therapy: Expert Opin Pharmacother; 6 (10): 1657-1668.

Zupanic-Krmek D; Nemet D; Mrsic M; Bogdanic V; Labor B; Jandrlic M; Kalenic S (2004): Risk factors for invasive fungal infections during intensive chemotherapy of acute leukemia—retrospective study. (ABSTRACT) Acta Med Croatica; 58 (4): 275-284.